Pooled Intravenous Immunoglobulin in the Management of Systemic Vasculitis

  • David R. W. Jayne
  • C. Martin Lockwood
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 336)

Summary

Investigation into the therapeutic use of intravenous immunoglobulin (IVIg) in systemic vasculitis was prompted by the detection of anti-idiotype antibodies reactive with ANCA in IVIg and the proven ability of IVIg to reduce the incidence of coronary artery aneurysms in Kawasaki disease. The efficacy and safety of IVIg (Sandoglobulin) was assessed in an open study of 26 patients with active systemic vasculitis. Eight weeks after IVIg 13 patients were in full and 13 in partial remission, clinical benefit was maintained in 18 twelve months later and was reflected by changes in C-reactive protein and ANCA.

Keywords

Kawasaki Disease Partial Remission Intravenous Immunoglobulin Systemic Vasculitis Coronary Artery Aneurysm 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cohen Tervaert, J.W., Huitema, M.G., Hené, R.J., Sluiter, W.J., The, T.H., Van der Hem, G.K., Kallenberg, C.G.M. 1990. Prevention of relapses in Wegener’s granulomatosis by treatment based on antineutrophil cytopalsmic antibody titre. Lancet II: 709–711Google Scholar
  2. Cohen, J., Pinching, A.J., Rees, A.J., Peters, D.K. 1982. Infection and immunosuppression: a study of the infective complications of 75 patients with immunologically mediated disease: Q.J. Med. 51: 1–15PubMedGoogle Scholar
  3. Fauci, A.S., Katz, P., Haynes, B.F., Wollf, S.M. 1979. Cyclophosphamide therapy of severe systemic necrotizing vasculitis. N. Engl. J. Med. 301: 235–238PubMedCrossRefGoogle Scholar
  4. Jayne, D.R.W., Black, C.M., Davies, M., Fox, C., Lockwood, C.M. 1991. Tretment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet 337: 1137–1139PubMedCrossRefGoogle Scholar
  5. Jerne, N.K. 1974. Towards a network theory of the immune system. Ann. Immunol. ( Paris ) 125C: 373–389Google Scholar
  6. Kondo, N., Ozawa, T., Musihake, K., Motoyoshi, F., Kameyama, T., Kasahara, K., Kaneko, H., Yamashina, M., Kato, Y., Orii, T. 1991. Suppression of immunoglobulin production of lymphocytes by intravenous immunoglobulin. J. Clin. Immunol. 11: 152–158PubMedCrossRefGoogle Scholar
  7. Leung, D.Y.M., Cotran, R.S., Kurt-Jones, E., Burns, J.C., Newburger, J.W., Prober, J.S. 1989. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet I: 1298–1302Google Scholar
  8. Mathieson, P.W., Cobbold, S.P., Hale, G., Clark, M.J., Oliveira, D.B.G., Lockwood, C.M., Waldmann, H. 1990. Monoclonal antibody therapy in systemic vasculitis. N. Engl. J. Med. 323: 250–254PubMedCrossRefGoogle Scholar
  9. Neild, G.H. 1991. Infectious complications in the management of systemic vasculitis and rapidly progressive glomerulonephritis. APMIS 98 (Suppl 19): 56–60Google Scholar
  10. Rossi, F., Jayne, D.R.W., Lockwood, C.M., Kazatchkine, M.D. 1991. Anti-idiotypes against antineutrophil cytoplasmic antigen autoanbitodies in normal human polyspecific IgG for therapeutic use and in the remission sera of patients with systemic vasculitis. Clin. Exp. Immunol. 83: 298–303PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1993

Authors and Affiliations

  • David R. W. Jayne
    • 1
  • C. Martin Lockwood
    • 1
  1. 1.Department of Medicine School of Clinical MedicineUniversity of CambridgeUK

Personalised recommendations